Intrinsic Imaging Awarded Phase II Clinical Trial for Treatment of Advanced Squamous Cell Carcinoma (SCC)

Boston (MA), San Antonio (TX), March 31, 2015 - Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with advanced squamous cell carcinoma (SCC). 

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and imaging charter development, site qualification, site training and management, image transfer, blinding and processing of images acquired by computed tomography (CT) or magnetic resonance imaging (MRI). Subsequently, study treatment response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation criteria.

Intrinsic Imaging’s more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists, all with significant expertise in evaluation of many cancers and their metastases – including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal, skin and thyroid. Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related.

“Intrinsic Imaging is dedicated to applying its therapeutic and regulatory expertise throughout this clinical trial,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “Our team has significant experience and expertise in the design and management of oncology clinical trials and in the determination of drug efficacy and/or disease progression of advanced squamous cell carcinoma.”